How to Help Your Patients Save Money on Humulin N: A Provider's Guide to Savings Programs

Insulin affordability remains a critical concern for many patients with diabetes, even after significant price reductions in 2023-2024. As a prescriber, being familiar with the full landscape of Humulin N savings programs is essential for helping patients afford their medication and stay adherent. This guide covers every program and strategy available to help your patients reduce their Humulin N costs in 2026.

Current Humulin N Pricing Landscape

In Q4 2023, Eli Lilly cut the list price of Humulin N by 70%, reducing the retail price to approximately $82-$86 for a 10 mL vial and approximately $92 for a five-pack of KwikPens. Combined with Lilly's $35/month out-of-pocket cap and Medicare's inflation reduction act $35 cap, most patients should be paying no more than $35/month for Humulin N. However, many patients don't know about these programs, aren't enrolled, or face barriers that your team can help address.

Program 1: Lilly Insulin Value Program ($35/Month Cap)

The Lilly Insulin Value Program caps monthly out-of-pocket costs for Humulin N at $35 for:

Commercially insured patients (automatically applied at approximately 85% of U.S. retail pharmacies)

Uninsured patients paying cash (requires downloading a savings card at insulinaffordability.com)

Key clinical note: This program has no cap on the quantity of vials or pens dispensed per month (as long as prescribed), with a $16,000 annual coverage limit. There is no income requirement for this program.

Patient enrollment: insulinaffordability.com or call 1-833-808-1234. Commercially insured patients may already be receiving this automatically at participating pharmacies.

Practice tip: Post this URL in your office or include it on your patient education materials. Patients who are overpaying should be directed here immediately.

Program 2: Lilly Cares Foundation — Patient Assistance Program

For uninsured patients with limited income who do not qualify for or cannot use the commercial savings card, the Lilly Cares Foundation provides Humulin N at no cost:

Eligibility: Uninsured patients with limited income (most qualify within standard low-income thresholds)

Application: Provider completes and submits the application with the patient. Form available at lillycares.com. Submitted by mail or fax.

Authorization: Valid for one year; renewable

Contact: 1-800-545-6962

Practice tip: Have a copy of the Lilly Cares application on hand in your office. For patients who cannot afford any cost, this program is the most impactful option.

Program 3: Lilly Diabetes Solution Center

The Lilly Diabetes Solution Center (1-833-808-1234) provides personalized financial assistance navigation for patients using Lilly insulins. Representatives can help patients identify which program best fits their situation, enroll in the Insulin Value Program or Lilly Cares, and troubleshoot pharmacy billing issues. This is a useful referral for patients who are confused about which program to use.

Program 4: Medicare $35 Cap (Inflation Reduction Act)

Under the Inflation Reduction Act, Medicare Part D now caps insulin costs at $35 per month per covered insulin. This applies to Humulin N for Medicare enrollees. If your patient is on Medicare and reports paying more than $35/month for Humulin N, contact their Part D plan to investigate — they may not be correctly coded as an insulin fill or may need plan-level intervention.

Note: Medicare does NOT allow the simultaneous use of commercial manufacturer savings cards like the Lilly Insulin Value Program. The Medicare $35 cap is the primary savings mechanism for Medicare enrollees.

Program 5: Walmart ReliOn NPH — OTC Option for Uninsured Patients

Walmart's ReliOn NPH insulin (insulin isophane human, NPH) is pharmacologically equivalent in class to Humulin N and is available over the counter at approximately $25 per 10 mL vial (100 units/mL). For uninsured patients who need an immediate low-cost option, this is often the most accessible solution.

Clinical note: The products are pharmacologically equivalent in class but are manufactured differently. If you have a patient who is stable on Humulin N, a switch to ReliOn NPH should be done with close monitoring. Document the reason for the switch (cost/accessibility) in the patient record. The dosing does not need to change.

Program 6: State-Level Insulin Safety Net Programs

Several states have enacted their own insulin affordability laws and safety net programs. For example, Minnesota operates an Insulin Safety Net program that provides emergency insulin supplies at no cost to qualifying residents. Check your state's health department or RxAssist.org (rxassist.org) and NeedyMeds.org for state-specific programs.

Building Insulin Affordability Into Your Practice Workflow

Consider implementing these workflows at your practice to proactively address affordability:

Standardize the affordability conversation. Ask every insulin-prescribing visit: "Are you having any trouble affording or finding your insulin?" This opens the door to cost and access discussions before a crisis occurs.

Keep a savings resource sheet at the front desk. A one-page summary of insulinaffordability.com, Lilly Cares, and Walmart ReliOn should be available for every insulin patient.

Pre-authorize early refills for insulin patients. Note in the prescription that early refills are permitted (for insulin-dependent patients) to give them buffer time if their pharmacy runs low.

Consider mail-order for stable patients. 90-day mail-order supplies are often cheaper than retail 30-day fills, and they reduce the risk of patients encountering retail pharmacy stock gaps.

How medfinder Supports Your Patients' Access

When patients can't find Humulin N in stock at their pharmacy, directing them to medfinder.com/providers helps them locate nearby pharmacies with stock without burdening your staff. medfinder calls pharmacies near the patient and texts results back. This is particularly valuable when localized stock gaps are affecting your patient population. See also: Humulin N Shortage Update: What Patients Need to Know in 2026.